CNS Pharmaceuticals, Inc.
CNSP
$4.59
-$0.30-6.14%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -49.26% | 166.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.89% | 84.00% | |||
| Operating Income | 16.89% | -84.00% | |||
| Income Before Tax | 17.11% | -85.05% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 17.11% | -85.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.11% | -85.05% | |||
| EBIT | 16.89% | -84.00% | |||
| EBITDA | 16.91% | -84.00% | |||
| EPS Basic | 24.75% | -68.48% | |||
| Normalized Basic EPS | 24.75% | -68.48% | |||
| EPS Diluted | 24.75% | -68.45% | |||
| Normalized Diluted EPS | 24.75% | -68.48% | |||
| Average Basic Shares Outstanding | 10.17% | 9.82% | |||
| Average Diluted Shares Outstanding | 10.17% | 9.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||